EMA Will Increase Fees on April 1
The European Commission has applied to increase the fees payable to EMA by 0.2%, which in line with the 2015 inflation rate.
You’ve only got another two weeks to submit applications to the European Medicines Agency (EMA) before the fees go up. The new charges for all applications except pharmacovigilance procedures will take effect on April 1.
The European Commission has applied to increase the fees payable to EMA by 0.2%, which in line with the 2015 inflation rate. EMA has said it will publish full details of the revised fees at the end of March, once the European Commission has adopted the regulation and published it in the Official Journal of the European Union and the Agency's Management Board has reached a decision on its implementation.
All applications received by March 31 will be charged at the current fee and reduction rates, according to EMA. For scientific advice and protocol assistance, the cut-off date will be the date of validation of the request for advice. For annual fees, the anniversary date defines the applicable fee and consequently any anniversary on or after April 1, 2016 will attract the new fee.
Fees charged for pharmacovigilance procedures in accordance with Regulation (EU) 658/2014 are expected to be updated from July 1, 2016.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
